New cell combo therapy tested for advanced cancers
NCT ID NCT07407985
First seen Feb 17, 2026 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This early-phase study tests a new cell treatment (GK01) combined with an immunotherapy drug (PD-1 antibody) in 15 adults with advanced solid tumors that have spread or come back. The main goal is to check safety and how the body handles the treatment, while also looking at whether tumors shrink or stop growing. It is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.